US-based Masimo, known for its non-invasive patient monitoring technologies has set its sights on India foray with its range of bed side diagnostic equipment. These include pulse oximetry equipment and its varied versions which could detect life-threatening conditions.
Indian healthcare space is quite familiar with the Masimo technologies. Now the company has several hospitals and nursing homes including Fortis Escorts Heart Institute, New Delhi; Arpan Nursing Home, Ahmedabad and Manipal Hospital, Bengaluru using its products to save patients. This led the company to set up its base in Bengaluru manned with sales, marketing and clinical staff. The company is looking to further strengthen its distributor link across the country for faster access to healthcare providers.
Globally Masimo employs over 3,000 personnel. It has technology license and OEM agreements with leading patient monitoring manufacturers including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll.
“We have found that India is an important market because of the low penetration of high technology devices, as a leader in non-invasive patient monitoring, including measure through motion and low perfusion pulse oximetry, our technologies will be able to make a significant impact to improve patient safety and outcomes here,” said Jon Coleman, president, Masimo Worldwide Sales, Professional Services and Medical Affairs.
In order to gain a better foothold into the Indian market, it is working with India’s top medical and nursing practitioners to raise awareness of the clinical and cost challenges that Masimo’s innovative technologies can solve.
The Masimo range for India covers: SET Measure-through Motion and Low Perfusion pulse provides measurements when other pulse oximeters cannot. It dramatically reduces false alarms and accurately detects true alarms to indicate a deteriorating patient. Further, the monitoring device has also been able to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP) in neonates, screen newborns for critical congenital heart disease (CCHD), reduce ventilator weaning time and arterial blood gas measurements in the ICU.
Its Rainbow pulse CO-Oximetry monitors multiple blood constituents, such as total haemoglobin to help clinicians reduce unnecessary blood transfusions in both low and high blood-loss surgery situations. The carboxyhemoglobin is a first-line assessment tool for clinicians to detect carbon monoxide (CO) poisoning.
Methemoglobin assesses the dangerous reaction to some hospital-administered drugs that reduces the delivery of oxygen to the tissues.
Other Masimo technologies are RAM acoustic respiration rate system which is an effective capnography or nasal cannula, better tolerated by patients.
The Root is a new connectivity platform that integrates Rainbow and SET measurements with multiple additional parameters including SedLine brain function monitoring, Phasein capnography and gas monitoring empowering clinicians to make quick patient assessments and earlier interventions.
Masimo Patient SafetyNet, a remote monitoring and clinician notification system keeps patients safer as its checks of the physiology, including oxygenation and pulse rate, which has led to saving lives.